PT - JOURNAL ARTICLE AU - Oni-Orisan, Akinyemi AU - Haldar, Tanushree AU - Cayabyab, Mari A. S. AU - Ranatunga, Dilrini K. AU - Hoffmann, Thomas J. AU - Iribarren, Carlos AU - Krauss, Ronald M. AU - Risch, Neil TI - Polygenic risk score and statin relative risk reduction for primary prevention in a real-world population AID - 10.1101/2021.07.28.21254571 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.28.21254571 4099 - http://medrxiv.org/content/early/2021/07/29/2021.07.28.21254571.short 4100 - http://medrxiv.org/content/early/2021/07/29/2021.07.28.21254571.full AB - Background Randomized-controlled trials demonstrate that high coronary heart disease (CHD) polygenic risk score modifies statin CHD relative risk reduction, but it is unknown if the association extends to statin users undergoing routine care.Objectives The primary objective was to determine how statin effectiveness is modified by CHD polygenic risk score in a real-world cohort of primary prevention participants.Methods We determined polygenic risk scores in participants of the Genetic Epidemiology Research on Adult Health and Aging (GERA) cohort. Cox regression models were used to compare the risk of the cardiovascular outcomes between statin users and matched nonusers.Results The hazard ratio (HR) for statin effectiveness on incident myocardial infarction was similar within 10-year atherosclerotic cardiovascular disease (ASCVD) risk score groups at 0.65 (95% confidence interval [CI] 0.39-1.08; P=0.10), 0.65 (95% CI 0.56-0.77; P=2.1E-7), and 0.67 (95% CI 0.57-0.80; P=4.3E-6) for borderline, intermediate, and high ASCVD groups, respectively. In contrast, statin effectiveness by polygenic risk was largest in the high polygenic risk score group (HR 0.62, 95% CI 0.50-0.77; P=1.4E-5), intermediate in the intermediate polygenic risk score group (HR 0.70, 95% CI 0.61-0.80; P=5.7E-7), and smallest in the low polygenic risk score group (HR 0.86, 95% CI 0.65-1.16; P=0.33). ASCVD risk and statin LDL-C lowering did not differ across polygenic risk score groups.Conclusions In primary prevention patients undergoing routine care, CHD polygenic risk modified statin relative risk reduction of incident myocardial infarction independent of statin LDL-C lowering. Our findings extend prior work by identifying a subset of patients with attenuated clinical benefit from statins.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants RC2 AG036607, K01 HL143109, and P50 GM115318 from the National Institutes of Health (NIH). The development of the Research Program on Genes, Environment, and Health was supported by grants from the Robert Wood Johnson Foundation, the Wayne and Gladys Valley Foundation, the Ellison Medical Foundation, and Kaiser Permanente Community Benefit Programs.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval was obtained from Kaiser Permanente and University of California Institutional Review Boards. Participants gave written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe used data from participants in Genetic Epidemiology Research on Adult Health and Aging (GERA), a resource of the Research Program on Genes, Environment and Health (RPGEH) within the Kaiser Permanente Northern California (KPNC) health system that links electronic health record, genome-wide variant, and demographic survey data (9, 10) as described in the Supplemental Methods. https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000674.v2.p2 ASCVDAtherosclerotic cardiovascular diseaseCHDcoronary heart diseaseLDL-Clow-density lipoprotein cholesterolMACEmajor adverse cardiovascular events